Alimera Sciences Inc patents expiration
1. Iluvien patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6217895 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US6548078 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US8252307 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Jun, 2019
(4 years ago) | |
| US6375972 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(3 years ago) | |
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2017 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Treatment of diabetic macular edema
Dosage: IMPLANT;INTRAVITREAL
More Information on Dosage
ILUVIEN family patents
2. Yutiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6548078 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US6217895 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US8252307 | ALIMERA SCIENCES INC | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Jun, 2019
(4 years ago) | |
| US9849085 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(3 years ago) | |
| US9192579 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(3 years ago) | |
| US8574659 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(3 years ago) | |
| US6375972 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(3 years ago) | |
| US8574613 | ALIMERA SCIENCES INC | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr, 2020
(3 years ago) | |
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
| US7998108 | ALIMERA SCIENCES INC | Injector apparatus and method of use |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 12, 2021 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 12 October, 2018
Treatment: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; A method of injecting an implant
Dosage: IMPLANT;INTRAVITREAL
More Information on Dosage
YUTIQ family patents